Medaphor losses widen on increased R&D investment
Ultrasound software developer Medaphor warned investors on Monday that losses looked likely to have widened in its last trading year despite improved revenues.
FTSE AIM All-Share
739.00
16:54 01/11/24
n/a
n/a
Health Care Equipment & Services
10,406.99
17:14 01/11/24
1.39%
142.56
Intelligent Ultrasound Group
11.50p
16:55 01/11/24
2.22%
0.25p
Medaphor, which reported 27% higher revenues of £5.3m to £5.4m, also expected adjusted operating losses to have widened roughly 76% year-on-year to £3m.
The AIM-listed outfit said the loss was principally a result of around £1.5m in research and development expenses stemming from its investment into its clinical artificial intelligence division.
MedaPhor received £4.86m in December as a result of a placing and open offer - giving it a year-end cash balance of £5.5m.
As of 1035 GMT, Medaphor shares had slipped 3.23% to 7.50p.